News

Promacta is a once-daily oral thrombopoietin (TPO) receptor agonist that works by inducing stimulation and differentiation of megakaryocytes from bone marrow stem cells to increase platelet production. The

The fully randomized placebo-controlled trial, conducted by Moore Clinical Research, an independent FDA-compliant contract research organization (CRO), compares the performance of HSRx’s acne treatment product with that of

Retinitis pigmentosa leads to the progressive degeneration of rod and cone photoreceptors (cells found in the retina that sense light), resulting in severe vision loss and blindness. With

Talazoparib is currently in a Phase III trial designed to treat patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.

Bavituximab is Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor and durvalumab is AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, while both are investigational immunotherapies with different mechanisms that assist the

The global clinical trial technology company has centralized development of its SaaS solutions in its Boston office due to the area’s unique combination of expert development talent, biopharmaceutical

Her addition to the senior leadership team further solidifies EAS as the leading consulting company in regulatory matters pertaining to all FDA regulated areas including OTCs, pharmaceuticals, cosmetics,

HPPI will study the efficacy and safety of twice-daily dosing of SUBA-Itraconazole Oral Capsules as a potential therapy for basal cell carcinoma (BCC) in patients with basal cell

Of 203 total subjects enrolled in VTI-208, 96 were randomized to the treated group and 107 were randomized to the control group. A hazard ratio of 1.027 (slightly